A 12-week open-label study with 3 within-patient double-blind placebo-controlled periods to evaluate the efficacy and safety of OraVescent fentanyl citrate treatment for the management of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain
Latest Information Update: 10 Feb 2011
At a glance
- Drugs Fentanyl (Primary)
- Indications Pain
- Focus Registrational; Therapeutic Use
- Sponsors Cephalon
- 09 Nov 2007 Status changed from in progres to completed
- 12 Dec 2006 New trial record.